Search

UCB SA

Geschlossen

BrancheGesundheitswesen

203.3 1.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

203.1

Max

203.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

28M

1.1B

Verkäufe

16M

4.3B

KGV

Branchendurchschnitt

17.747

47.946

EPS

5.7

Dividendenrendite

0.71

Gewinnspanne

26.019

Angestellte

9,000

EBITDA

587M

1.4B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.23% upside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

0.71%

2.27%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-8.5B

38B

Vorheriger Eröffnungskurs

201.9

Vorheriger Schlusskurs

203.3

UCB SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Okt. 2026, 00:01 UTC

News

Mesa Laboratories Inc announced a quarterly dividend of $0.16 per share, with a record date of November 30, 2026, and payment on December 15, 2026.

9. Okt. 2026, 23:50 UTC

News

Constellation Brands Inc shares are modestly higher in after-market trading as analysts assess the company's valuation amid its focus on beer, wine, and spirits.

9. Okt. 2026, 23:25 UTC

News

Aon PLC declared a quarterly dividend of $0.820 per share, payable on November 13, 2026, and confirmed third-quarter earnings release for October 28, 2026.

9. Okt. 2026, 23:15 UTC

News

PayPal Holdings Inc is trading lower in after-hours activity, focusing on expanding credit offerings and Buy Now Pay Later services while planning share buybacks.

9. Okt. 2026, 23:15 UTC

News

Coca-Cola Consolidated Inc. declared a quarterly dividend of $0.25 per share, payable on November 6, 2026, to shareholders on record as of October 23, 2026.

9. Okt. 2026, 23:10 UTC

News

EnerSys receives a strong buy designation from Wall Street analysts, driven by optimism about AI infrastructure's impact on the data center sector.

9. Okt. 2026, 23:05 UTC

News

Truist Financial announces a $250K grant to support Gulf Coast communities' relief and recovery efforts ahead of Hurricane Isaias.

9. Okt. 2026, 23:05 UTC

News

JP Morgan reaffirms Overweight rating on Parker-Hannifin Corp, lowering its price target to $1.13K in a report released after the market closed.

9. Okt. 2026, 23:05 UTC

News

DICK'S Sporting Goods faces two class action lawsuits alleging securities fraud related to its business performance and disappointing financial results.

9. Okt. 2026, 23:01 UTC

News

Royal Caribbean Cruises Ltd is trading modestly lower in after-market hours, continuing a downward trend despite analysts suggesting the stock may be undervalued.

9. Okt. 2026, 23:01 UTC

Social Media
News

Perrigo Company PLC is reportedly under renewed takeover interest from an unidentified buyer, with speculation that CVC Capital may pursue an acquisition.

9. Okt. 2026, 23:01 UTC

News

Delta Air Lines Inc cut its guidance after missing third-quarter earnings and revenue estimates, with shares trading modestly lower in after-market hours.

9. Okt. 2026, 23:01 UTC

News
Social Media

Verizon shares are trading higher in after-market hours, despite reports of its worst trading day since 2002 amid competitive pressures from SPCX and T-Mobile's decline.

9. Okt. 2026, 22:50 UTC

News
Social Media

Star Bulk Carriers announces a partnership with Hermes World Maritime and renews equity offerings with Deutsche Bank for $41.37M and Jefferies for $75M.

9. Okt. 2026, 22:50 UTC

News

GoDaddy faces a class action lawsuit from Pomerantz LLP alleging securities fraud and unlawful business practices, encouraging affected shareholders to join by October 20, 2026.

9. Okt. 2026, 22:21 UTC

News

CareTrust REIT, Inc. released its sixth annual Corporate Sustainability Report, highlighting advancements in sustainability initiatives and adherence to ISS ESG Prime status.

9. Okt. 2026, 22:20 UTC

News

Mesa Laboratories Inc announced a quarterly dividend of $0.16 per share, payable on December 15, 2026, to shareholders of record on November 30, 2026.

9. Okt. 2026, 21:01 UTC

Correlated Moves
News

USD/PLN is gaining and remains above its 20-day moving average, near the upper end of its one-month range, despite earlier pulling back from a session high.

9. Okt. 2026, 20:41 UTC

News
Correlated Moves

USD/SEK is modestly higher, supported by an increase in the U.S. Baker Hughes total rig count to 603 from 598.

9. Okt. 2026, 20:40 UTC

News

Standard Motor Products announces CFO Nathan R. Iles' resignation effective October 30, 2026, with James J. Burke as interim CFO, prompting a decline in after-market trading.

9. Okt. 2026, 20:07 UTC

News

United Parcel Service Inc shares are higher, supported by plans to hire 100k seasonal workers and new services aimed at enhancing parcel security and pricing power.

9. Okt. 2026, 20:07 UTC

News
Correlated Moves
Social Media

Microsoft introduces its new AI model, Microsoft-Decision-1, which reportedly makes decisions 35 times faster than OpenAI's GPT-6 Sol, as announced by CEO Satya Nadella.

9. Okt. 2026, 20:07 UTC

News

Baird analyst Andrew Wittmann lowered Construction Partners Inc's price target to $115.00 from $141.00 while maintaining an Outperform rating.

9. Okt. 2026, 20:07 UTC

News

Barclays analyst Michael Lonegan lowers Idacorp's price target to $149.00 from $162.00 while maintaining an Overweight rating.

9. Okt. 2026, 20:07 UTC

Macro Event
News

Evercore ISI maintains its Underperform rating on Franklin Resources, lowering the price target to $35, contributing to a decline in the stock.

9. Okt. 2026, 20:07 UTC

Macro Event
News

Dollar General shares advanced, buoyed by broader market gains, despite earlier pulling back from a session high, amid a significant drop in consumer sentiment.

9. Okt. 2026, 20:07 UTC

News

UBS reaffirms Buy rating on Biogen Inc and raises price target to $270 from $240, while CCB International initiates coverage with an Outperform rating.

9. Okt. 2026, 20:07 UTC

Correlated Moves
News
Social Media

Viking Therapeutics is seeing increased interest amid reports of a potential bidding war, with speculation about suitors including LLY and positive momentum in the biotech sector.

9. Okt. 2026, 20:07 UTC

News

Schrodinger Inc rebounds amid volatility, supported by a $1.8 billion Biohub partnership announced by the White House focusing on AI-ready biological data.

9. Okt. 2026, 20:07 UTC

Social Media
News

Raymond James initiated coverage on Kymera Therapeutics Inc with an Outperform rating and set a price target of $140.

Peer-Vergleich

Kursveränderung

UCB SA Prognose

Kursziel

By TipRanks

19.23% Vorteil

12-Monats-Prognose

Durchschnitt 94.86 EUR  19.23%

Hoch 125 EUR

Tief 74 EUR

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für UCB SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

1

Halten

2

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.